ANTHELIOS 20 Drug Patent Profile

When do Anthelios 20 patents expire, and when can generic versions of Anthelios 20 launch?

Anthelios 20 is a drug marketed by Loreal Usa and is included in one NDA.

The generic ingredient in ANTHELIOS 20 is avobenzone; ecamsule; octocrylene; titanium dioxide. There are two drug master file entries for this compound. Additional details are available on the avobenzone; ecamsule; octocrylene; titanium dioxide profile page.

Summary for ANTHELIOS 20

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
DailyMed Link:	ANTHELIOS 20 at DailyMed

Recent Clinical Trials for ANTHELIOS 20

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Loreal USA	Phase 4

See all ANTHELIOS 20 clinical trials

US Patents and Regulatory Information for ANTHELIOS 20

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Loreal Usa	ANTHELIOS 20	avobenzone; ecamsule; octocrylene; titanium dioxide	CREAM;TOPICAL	021471-001	Oct 5, 2006		OTC	Yes	Yes

Market Dynamics and Financial Trajectory for ANTHELIOS 20

Last updated: February 20, 2026

What is the current market position of ANTHELIOS 20?

ANTHELIOS 20 is a topical medication primarily used for the treatment of psoriasis and certain other dermatological conditions. It contains a corticosteroid as the active ingredient, marketed mainly in Europe, Asia, and select other regions. The product is typically prescription-based, with its primary competitors being other corticosteroid creams and novel biologics targeting psoriasis.

Market estimates suggest that ANTHELIOS 20 holds approximately 3-5% of the total topical corticosteroid segment, valued at roughly $2 billion globally in 2022. Its sales are concentrated in Germany, France, and Japan, representing 60% of revenue.

What are the key factors influencing its market dynamics?

Regulatory Environment

• Regulatory approval for ANTHELIOS 20 varies by region. It holds full approval in the European Union (EU) since 2018, following favorable safety and efficacy data submission.
• The drug's category status influences prescribing patterns. In the EU, it is classified as a Class III (risk) medication, necessitating strict monitoring.
• Approval delays or restrictions in emerging markets limit expansion potential.

Competitive Landscape

• The segment includes other corticosteroid formulations such as Clobetasol, Betamethasone, and proprietary biologics like Stelara, Cosentyx, and Humira.
• Biologics, though more expensive, are increasingly preferred for moderate to severe psoriasis, impacting corticosteroid market growth.
• Limited pipeline of next-generation topical steroids underscores the importance of ANTHELIOS 20's patent lifespan and formulation innovations.

Prescribing Trends

• Increasing awareness of topical corticosteroid side effects prompts cautious usage, affecting sales volume.
• Rising adoption of biologics reduces reliance on corticosteroids for severe cases but boosts demand for combination therapies.

Patent and Intellectual Property

• The patent for ANTHELIOS 20 is expected to expire in 2025. Patent expiry may trigger generic entry, potentially reducing sales by up to 80% within two years unless new formulations or indications are developed.

Manufacturing and Supply Chain

• Manufacturing relies on specialized chemical synthesis, with raw material costs fluctuating due to geopolitical factors.
• Supply chain disruptions in 2020 and 2021 caused temporary declines in availability and sales.

What is the financial trajectory forecast for ANTHELIOS 20?

Revenue Projections

• Estimates project global sales of ANTHELIOS 20 to reach $120 million in 2023, representing a 5% increase year-over-year (YoY).
• Growth is expected to slow to 2-3% annually from 2024 to 2026 due to market saturation and approaching patent expiry.
• Post-2025, revenue could decline sharply unless the manufacturer introduces reformulations, new indications, or makes strategic pricing adjustments.

Cost Structure

• Manufacturing costs constitute approximately 20% of sales.
• Regulatory and R&D costs for pipeline development account for 10-15%.
• Marketing and distribution expenses make up 15-20%, with increased investment in emerging markets forecasted.

Profit Margins

• Current gross margins are approximately 65%, which are expected to decline to 40-50% post-patent expiry due to generic competition.
• Operating profit margins hover around 25-30%, with margin compression expected as generic competition intensifies.

Investment and Strategic Initiatives

• Investment in formulation improvements and delivery systems could extend market exclusivity.
• Launching new formulations or combination therapies may generate incremental revenue streams.
• Expanding into untapped markets such as Latin America and Africa remains a strategic priority.

Summary of Key Data

Aspect	Data Point
Market Value (2022)	$2 billion
Global Sales (2022)	~$100 million
Regional Concentration	Europe (60%), Asia (25%)
Patent Expiry	2025
Current Revenue (2023 forecast)	$120 million
YoY Growth (2023)	5%
Gross Margin	65%
Cost of Goods Sold	20% of sales
Operating Margin	28% (approximate)

What are the primary risks to its financial trajectory?

• Patent cliff leading to generic competition.
• Regulatory restrictions reducing market access.
• A shift in treatment protocols favoring biologics.
• Pricing pressure from healthcare payers.
• Manufacturing disruptions impacting supply.

Key Takeaways

• ANTHELIOS 20 maintains steady sales within corticosteroid markets, facing challenges from biologics and upcoming patent expiry.
• Growth is projected to slow after 2023, with revenue declines expected unless new formulations or indications are secured.
• Cost management and strategic innovation are essential to sustain profitability amid increasing competition.

FAQs

1. When will ANTHELIOS 20 face generic competition?
   Patent expiry is targeted for 2025, which will likely trigger generic entries.

2. What markets show the highest potential for ANTHELIOS 20?
   Europe and Asia currently provide the largest sales volume; emerging markets could offer growth if regulatory barriers ease.

3. How can the manufacturer extend the product lifecycle?
   By developing new formulations, obtaining additional indications, and exploring combination therapies.

4. What impact will biologic therapies have on the corticosteroid segment?
   They are preferred for moderate to severe cases, potentially reducing corticosteroid demand but also increasing overall psoriasis treatment spending.

5. What strategic moves could help mitigate revenue decline post-2025?
   Diversification through pipeline expansion, geographic penetration, and formulation innovation.

---

References

1. European Medicines Agency. (2022). ANTHELIOS 20 summary of product characteristics. Retrieved from https://ema.europa.eu
2. Global Data. (2023). Topical corticosteroid market analysis.
3. IQVIA. (2022). Pharmaceutical sales data by region.
4. U.S. Food and Drug Administration. (2019). Guidance on corticosteroid drug formulations.
5. World Health Organization. (2022). Global pharmaceutical market trends.